Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Expression Pathology to Collaborate in $300,000 Alberta Breast Cancer Research

Published: Tuesday, September 30, 2008
Last Updated: Tuesday, September 30, 2008
Bookmark and Share
EPI will employ its tissue proteomics technologies to identify protein biomarkers of metastasis.

Expression Pathology Inc. (EPI) will collaborate with the Alberta Cancer Board, Tom Baker Cancer Centre (Calgary, Alberta) to identify protein biomarkers of breast cancer metastasis. The project is funded by a $300,000 CAD grant from the Alberta Cancer Board and Foundation, a leading funding body for collaborative cancer research in Alberta.

EPI will employ its proprietary tissue proteomics technologies to study archived formalin-fixed breast cancer tissue samples from patients treated at the Tom Baker Cancer Centre. EPI’s Liquid Tissue® sample preparation and Director™ laser microdissection will enable in-depth mass spectrometry analysis of tissue samples that have detailed pathology and clinical outcome data.

Over 200,000 cases of early-stage breast cancer present for treatment decisions each year in North America. Proteins make up the molecular pathways which control cell functions and are the targets of drug action. This protein-based approach may yield valuable tissue biomarkers of breast cancer metastasis as well as potential new cancer drug targets.

“Assessment of the state of metastasis of breast cancer patients is key to optimal treatment decisions,” says Dr. Anthony Magliocco, Director of Pathology at the Tom Baker Cancer Centre and Associate Professor of Oncology, Pathology and Laboratory Medicine at the University of Calgary. “Our project with EPI will strive to identify proteins in primary tumor tissue that may serve as biomarkers of the early stages of metastasis at the molecular level.”

“This project is exactly how we see our proprietary tissue proteomics research platform being used, to understand at the protein level the progression of metastasis in early-stage breast cancer,” says Casimir Eitner, EPI’s President and CEO.

“Our aim is to develop valuable tissue protein assays that can aid patient treatment decisions and to identify new therapeutic targets and companion diagnostics to those targets. We greatly appreciate the Alberta Cancer Board’s support of this innovative initiative and recognition of the value of our company’s technology,” Eitner says.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Expression Pathology Obtains Second U.S. Liquid Tissue® Patent
Patent cover methods that increase the range of proteins and protein modifications which can be analyzed using the company’s patented Liquid Tissue® method.
Sunday, April 10, 2011
Expression Pathology Provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development
The Liquid Tissue®-SRM Technology accelerates identification of cancer molecular markers for developing more effective treatments.
Wednesday, January 12, 2011
Expression Pathology provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development
Expression Pathology Inc. announced an agreement with Roche wherein Expression Pathology will provide its Liquid Tissue®-SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.
Tuesday, January 11, 2011
Flagship Partners with Expression Pathology to Combine Tissue Proteomics and Digital Pathology
Two leading companies offer clients integrated services for digital pathology and quantitative mass-spec based tissue proteomics.
Sunday, December 12, 2010
Expression Pathology’s Liquid Tissue Patent Issues in Japan
Patent covers tissue processing methods to enable discovery and accurate measurement of protein biomarkers in standard FFPE tissue by mass spectrometry.
Tuesday, September 28, 2010
Key U.S. Patent Issues on Expression Pathology’s Liquid Tissue® Technology
The patent claims methods to enable protein analysis in FFPE tissue for clinical research and diagnostics.
Wednesday, January 07, 2009
EPI Licenses Harvard’s AQUA™ Peptide Technology
Company licenses the patent rights for mass spectrometry quantitation of proteins in patient tissue.
Wednesday, August 30, 2006
Publication Shows Cancer Biomarker Identification in Formalin-Fixed Tissue
The article describes LC MS/MS mass spectrometry analysis of FFPE prostate cancer tissue.
Thursday, November 10, 2005
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Rapid Retrieval of Live, Infectious Pathogens from Clinical Samples
An engineered pathogen-binding protein enables rapid isolation of infectious bacteria from joint fluids and accelerates their identification.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Detecting Fake Parmesan Cheeses
Scientists report on a way to catch adulteration of the regional artisanal products.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Process Analysis in Real Time
With a real-time mass spectrometer developed by Fraunhofer researchers, it has become possible for the first time to analyze up to 30 components simultaneously from the gas phase and a liquid, including in-situ analysis.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!